Welcome to our dedicated page for THERIVA BIOLOGICS SEC filings (Ticker: TOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Theriva Biologics, Inc. (TOVX) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Theriva’s clinical-stage programs, capital structure, and corporate actions, complementing its press releases and scientific presentations.
Investors can review Form 10-K and Form 10-Q annual and quarterly reports for discussions of risk factors, research and development activities, and financial condition related to programs such as VCN-01, SYN-004 (ribaxamase), SYN-020, and the VCN-X discovery efforts. Current reports on Form 8-K describe material events, including clinical data announcements, regulatory feedback from agencies such as the European Medicines Agency, warrant inducement agreements, public offerings, and at-the-market sales agreements.
Theriva’s proxy statements on Schedule 14A outline matters submitted to stockholders, such as proposals to approve the issuance of additional common shares upon exercise of warrants issued in private placements. These documents explain voting mechanics, record dates, and the rationale for share authorization requests tied to financing transactions.
Forms related to securities offerings, such as registration statements and prospectus supplements referenced in 8-K filings, describe the terms of public offerings of common stock and warrants, as well as at-the-market programs through placement agents. Together, these filings help clarify how Theriva funds the development of its clinical pipeline.
On this page, Stock Titan pairs Theriva’s SEC filings with AI-powered summaries that highlight key points, such as changes in capital structure, new clinical or regulatory disclosures, and important risk factor updates. Real-time updates from EDGAR, along with structured access to historical filings, allow users to monitor how Theriva’s regulatory and financing profile evolves alongside its investigational therapies.
Theriva Biologics, Inc. is asking shareholders to approve the issuance of up to 16,184,560 shares of common stock upon exercise of newly issued common stock purchase warrants, a proposal tied to a warrant inducement completed on October 17, 2025. The board says approval would permit exercise of the New Warrants at a stated exercise price of $0.54 per share and could generate up to $8.7 million in gross proceeds if fully exercised for cash.
The New Warrants were issued as part of an inducement arrangement and are exercisable only after stockholder approval; they include beneficial ownership caps of 4.99% (or, at holder election, 9.99%) and typical adjustment and fundamental-transaction provisions. As of the record date there were 45,892,668 shares outstanding.
Theriva Biologics has out-licensed its SYN-020 program to Rasayana Therapeutics under an exclusive worldwide agreement. Theriva received a $300,000 upfront payment and is eligible for up to $16,000,000 in development milestones and up to $22,000,000 in sales milestones, plus tiered low- to mid-single-digit royalties on net sales and a share of sublicense revenue.
Rasayana will assume all responsibility and costs for developing and commercializing SYN-020, which has completed Phase 1 and is planned to enter Phase 2. The deal allows Theriva to focus resources on its lead pancreatic cancer program VCN-01 while retaining economic participation in any future SYN-020 success.
Theriva Biologics, Inc. was unable to convene its Special Meeting of Stockholders on February 11, 2026 because not enough shares were present to form a quorum. The meeting was intended to obtain stockholder approval for issuing up to 16,184,560 shares of common stock upon exercise of certain New Warrants under an October 16, 2025 inducement agreement.
The company plans to call a new stockholder meeting to seek this approval and will announce the date and time and send new proxy materials. Under the inducement agreement, unless investors waive the requirement, Theriva must call another meeting every 60 days until stockholder approval is obtained or the New Warrants are no longer outstanding.
Theriva Biologics, Inc.
The presentation includes forward-looking statements language under the Private Securities Litigation Reform Act of 1995, indicating that it discusses expectations and plans in addition to historical information. No new financial results or major transactions are described in this report itself; it primarily alerts investors to the availability of the updated presentation.
Theriva Biologics, Inc. reported an equity award to its senior leadership. On 01/05/2026, a reporting person who serves as director, CEO and CFO received an option grant over 475,000 shares of common stock at an exercise price of $0.241 per share.
The stock options become exercisable on a pro rata monthly basis over 36 months, starting on 02/01/2026, and are scheduled to expire on 01/04/2033 if not exercised. Following this grant, the reporting person held 475,000 derivative securities directly, aligning a portion of their compensation with the company’s future share performance.
Theriva Biologics, Inc. director John J. Monahan reported a new stock option grant. On 01/05/2026 he received stock options to buy 75,000 shares of common stock at an exercise price of $0.241 per share. The options become exercisable starting 02/01/2026 and expire on 01/04/2033. They vest on a pro rata monthly basis over 12 months, which means a portion of the options becomes available to exercise each month during the first year.
Theriva Biologics, Inc. reported an insider equity award to one of its directors. The Form 4 shows a grant of 75,000 stock options with an exercise price of $0.241 per share on 01/05/2026. These options become exercisable starting 02/01/2026 and expire on 01/04/2033. According to the footnote, the options vest on a pro rata monthly basis over 12 months, meaning the director earns a portion of the grant each month during the first year.
Theriva Biologics, Inc. reported a new equity award to one of its directors. On 01/05/2026, the director received 75,000 stock options to purchase common stock at an exercise price of $0.241 per share. These options are classified as derivative securities and are held directly by the reporting person.
The options begin to vest on 02/01/2026 and expire on 01/04/2033. They vest on a pro rata monthly basis over 12 months, meaning the award is spread evenly across a one-year period. Following this grant, the reporting person beneficially owns 75,000 derivative securities linked to Theriva Biologics common stock.
Theriva Biologics is asking stockholders to approve the potential issuance of up to 16,184,560 shares of common stock upon exercise of new common stock purchase warrants issued to institutional investors in an October 17, 2025 private placement. If all these New Warrants are exercised for cash at the initial $0.54 exercise price, the company could receive up to approximately $8.7 million in gross proceeds, but existing holders would be diluted when the shares are issued. As of the December 31, 2025 record date, there were 35,688,349 shares of common stock outstanding. A second proposal would allow adjournment of the February 11, 2026 special meeting to gather additional votes if needed. The Board unanimously recommends voting “FOR” both proposals.
Theriva Biologics disclosed that it has received formal Scientific Advice from the European Medicines Agency’s CHMP on the design of a planned Phase 3 trial for its lead candidate VCN-01 in first-line metastatic pancreatic adenocarcinoma. The advice indicates that a potential future marketing authorization application could be supported by a single, double-blinded, randomized, placebo-controlled Phase 3 study if it shows a compelling benefit-risk profile for VCN-01 plus gemcitabine/nab-paclitaxel standard-of-care versus chemotherapy alone.
CHMP agreed with key trial elements, including inclusion and exclusion criteria, overall survival as the primary endpoint, several secondary endpoints such as progression free survival and duration of response, sample size, and the use of an adaptive design. The committee also acknowledged the improved overall survival seen with two doses of VCN-01 in the prior VIRAGE Phase 2b trial and agreed with a repeated “macrocycle” dosing schedule that allows more than two doses in Phase 3, while suggesting that even more frequent dosing could be considered.